BioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD
Tweet Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX) announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
